DRRX | tickerfilter.com

Fundamental analysis

56%

Profitability 27%

Dept financing 49%

Liquidity 75%

Performance 82%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0 0%

1 Month

0 0%

3 Months

0 0%

6 Months

0 0%

1 Year

133.38%

2 Year

89.11%

Key data

Stock price

$1.91

P/E Ratio

0.00

DAY RANGE

$1.91 - $1.95

EPS

-$0.01

52 WEEK RANGE

$0.48 - $2.64

52 WEEK CHANGE

$138.75

MARKET CAP

19.718 M

YIELD

N/A

SHARES OUTSTANDING

31.054 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-12-2025

BETA

-0.27

PUBLIC FLOAT

AVERAGE 10 VOLUME

N/A

AVERAGE 30 VOLUME

N/A

Company detail

CEO: James E. Brown
Region: US
Website: durect.com
Employees: 80
IPO year: 2000

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

DURECT Corporation researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses.

DRRX - DURECT CORP